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Abstract Amyloidosis is characterized by extracellular deposits
of protein fibrils with a high content of L-sheets in secondary
structure. The protein forms together with proteoglycans amyloid
fibrils causing organ damage and serious morbidity. Intact
apolipoprotein A-I (apoA-I) is an important protein in lipid
metabolism regulating the synthesis and catabolism of high
density lipoproteins (HDL). Usually, apoA-I is not associated
with amyloidosis. However, four naturally occuring mutant
forms of apoA-I are known so far resulting in amyloidosis. The
most important feature of all variants is the very similar
formation of N-terminal fragments which were found in the
amyloid deposits (residues 1^83 to 1^94). The new insights in the
understanding of the association of apoA-I with HDL, its
metabolism, and its hypothesized structural findings may explain
a common mechanism for the genesis of apoA-I induced
amyloidosis. Here we summarized the specific features of all
known amyloidogenic variants of apoA-I and speculate about its
metabolic pathway, which may have general implications for the
metabolism of apoA-I.
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1. Introduction
Amyloidosis is characterized by extracellular accumulation
of protein ¢brils forming L-pleated sheets. The form of amy-
loidosis depends on the protein involved as the basic subunit
of the amyloid ¢bril [1^3]. Systemic forms of hereditary amy-
loidosis may be associated with variant forms of normally
soluble proteins such as transthyretin, ¢brinogen, gelsoline,
lysozyme and apolipoprotein A-I [1,2,4^8]. Non-hereditary
forms of amyloidosis can also occur, like the deposits of var-
iable fragments of the immunoglobulin light chains or degra-
dation products of the acute phase protein serum amyloid A
[9,10].
The association of amyloid ¢brils with plasma and extracel-
lular matrix proteins and proteoglycans leads to amyloid de-
posits which invade the extracellular spaces of organs destroy-
ing the tissue and its function, which usually leads to death
over time.
2. Apolipoprotein A-I
Apolipoprotein A-I (apoA-I) is the major protein compo-
nent of high density lipoproteins (HDL) [11^15]. ApoA-I has
several functions: (i) structural properties of HDL; (ii) cofac-
tor for the enzyme lecithin:cholesterol acyltransferase
(LCAT), which is essential for the reverse cholesterol trans-
port ; and (iii) interacting with membranes, which is required
for cholesterol e¥ux, hepatic uptake and interaction with oth-
er lipoprotein particles [16^20]. The protein is synthesized
both in the intestine and in the liver as a 267 amino acid
prepropeptide. The prepropeptide is intracellularly cleaved
to the 249 amino acid propeptide and secreted in the plasma.
The cleavage from the propeptide to the native apoA-I with
243 amino acids occurs within the plasma [21]. The mature
protein contains no carbohydrates; the only reported post-
translational modi¢cations represent acylation and phosphor-
ylation [22,23]. The comparison of the kinetics of human iso-
lated apoA-I and recombinant apoA-I derived from E. coli
revealed identical radioactive decay curves in normolipemic
rabbits [24]. Therefore, the human acylated and phosphoryl-
ated apoA-I and the non-posttranslational modi¢ed E. coli
derived apoA-I behave kinetically identical. Thus, these post-
translational modi¢cations of apoA-I do not seem to a¡ect
the in vivo metabolism of apoA-I, still they may play a role in
intracellular tra⁄cking. Mature plasma apoA-I is associated
with phospholipids forming a lipid poor HDL particle, the so-
called pre-L-1 HDL. This lipid poor HDL takes up phospho-
lipids and cholesterol forming the larger discoidal HDL (pre-
L-2 HDL). Finally, the esteri¢cation of cholesterol within the
HDL particle by the enzyme lecithin:cholesterol acyltransfer-
ase leads to the conversion of the discoidal HDL to the spher-
ic HDL (K-HDL) [25^27].
3. Amyloidogenic mutations of apolipoprotein A-I
Four apoA-I variants have been reported so far which
cause hereditary systemic amyloidosis in patients. The impor-
tant features of these amyloidogenic variants are summarized
in Table 1. The ¢rst case was reported by van Allen et al.
describing a kindred in which a single base mutation of gua-
nine to cytosine to the ¢rst base of codon 26 on exon 3 of the
apoA-I gene was identi¢ed as the underlying cause [28]. This
point mutation leads to a change in the corresponding amino
acid sequence. The amino acid glycine at position 26 was
replaced by an arginine (apoA-IIowa). The protein content of
the amyloid ¢brils contained an N-terminal fragment (residues
1^83) of mutant apoA-IIowa. The a¡ected patients su¡ered
from neuropathy and nephropathy [28^32]. Interestingly, the
a¡ected patients had in addition low plasma levels of HDL
and apoA-I [33].
The second amyloidotic apoA-I variant, described by Sou-
tar et al., resulted from a single base mutation in exon 4 of the
apoA-I gene [34]. The base thymine was displaced by guanine
resulting in displacement of the amino acid leucine with argi-
nine at amino acid position 60 (Leu60CArg). The amyloid
deposits were made of N-terminal fragments (residues 1^88,
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1^92, 1^93, 1^94) of the mutant apoA-I. The intact mutant
apoA-I was also found in the amyloid ¢brils coprecipitated
with serum amyloid A in trace amounts. However, no wild-
type apoA-I was seen in the studied tissues. Neuropathy was
not reported in these patients. The HDL and apoA-I serum
concentrations were not reported in these patients.
Another variant apoA-I causing hereditary amyloidosis was
reported by Booth et al. [35]. The mutation is a result of a
substitution of thymine to cytosine in exon 4 of the apoA-I
gene. The corresponding protein contains an arginine instead
of tryptophan (Trp50-Arg). The amyloid deposits were com-
posed of N-terminal fragments of the variant apoA-I corre-
sponding to residues 1^86, 1^92, 1^94. Neuropathy was not
detectable. The liver was the primary site of amyloidosis in the
studied patients. The HDL and apoA-I serum concentrations
were not reported in the patients.
The last reported amyloidogenic apoA-I mutation (Booth et
al.) [36] was caused by a mutation in exon 4 in which 35
nucleotides had been deleted and 5 nucleotides inserted. The
mutation in the apoA-I gene resulted in an amino acid se-
quence in which the amino acids 60^71 were substituted by
the two amino acids valine and threonine. The detected apoA-
I fragments in the amyloid ¢brils contained the N-terminal
residues 1^83 and 1^92 according to the residue numbers of
the wild-type sequence. The patients’ plasma levels of apoA-I
and HDL were signi¢cantly lower than in una¡ected individ-
uals. The a¡ected patients had primarily hepatic involvement.
4. In vivo characterization of amyloidogenic apoA-I
The metabolic pathway of amyloidogenic apoA-I causing
tissue deposition has not been elucidated yet. In this respect
the work of Rader et al. is of great interest. This group iso-
lated apoA-I from plasma of patients with the heterozygous
state of apoA-IIowa induced familial amyloidosis. They radio-
labelled the isolated apoA-I containing both the Gly26-Arg
variant and wild type, and studied its in vivo metabolism in
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Table 1
Amyloidogenic apo A-I variants
Mutation Exon Fragments Clinical symptoms Ref.
Gly26-Arg 3 1^83 Neuropathy, nephropathy, peptic ulcer, low HDL, low apoA-I [28^33]
Trp50-Arg 4 1^86, 1^92, 1^93 Non-neuropathic amyloidosis, renal failure [35]
Leu60-Arg 4 1^88, 1^92, 1^93, 1^94 Non-neuropathic amyloidosis, renal failure [34]
v(60^71)InsValThr 4 1^83, 1^92 Non-neuropathic amyloidosis, liver failure, low HDL, low apoA-I [36]
The currently known amyloidogenic variants are summarized. The di¡erent mutations, their genetic locations, the length of fragments within the
amyloidotic ¢brils, and their clinical symptoms are depicted.
Fig. 1. A: The in vivo kinetics of human recombinant apoA-
Iwildÿtype (b) and human recombinant apoA-IIowa (R) after radioio-
dination and injection into NZW rabbits are illustrated. All data
represent the mean of triplicates. The in vivo kinetics showed a de-
creased catabolism of apoA-IIowa compared to apoA-Iwildÿtype. B:
The analysis of density gradient ultracentrifugation of a serum sam-
ple obtained 1 h after simultaneous injection of radiolabeled human
recombinant apoA-Iwildÿtype (b) and human recombinant apoA-IIowa
(R) into NZW rabbits are shown. Two peaks of radioactivity ap-
peared in the density range of HDL (HDL2 : d = 1.063^1.125 g/ml;
HDL3 : d = 1.125^1.21 g/ml), which indicated that both apoA-I
forms were associated with HDL. The majority of apoA-Iwildÿtype
was associated with the HDL2 fraction, whereas the majority of
apoA-IIowa was associated with the HDL3 fraction. C: An FPLC
analysis of a serum sample obtained 1 h after injection of radiola-
beled human recombinant apoA-Iwildÿtype (b) and human recombi-
nant apoA-IIowa (R) into NZW rabbits is illustrated. Two peaks of
radioactivity re£ect the di¡erent association of the studied apoA-I
forms with HDL. The majority of apoA-Iwildÿtype appeared in the
¢rst peak at fraction 23^29 and in the second peak at fraction 30^
34. The majority of apoA-IIowa appeared in the second peak at frac-
tion 30^34, indicating an association with smaller HDL particles.
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both normal subjects and patients, subsequently. Their results
revealed both an increased catabolism and altered association
with the HDL fraction of apoA-I isolated from a¡ected pa-
tients [33]. To gain further insight into the metabolism of
apoA-IIowa, we established recombinant expression of this pro-
tein and its wildtype in transfected CHO cells [37]. After pu-
ri¢cation by reversed phase chromatography we radiolabelled
the recombinant form of apoA-IIowa, and injected it simulta-
neously with wild type in New Zealand White (NZW) rabbits
using 131I and 125I, respectively [38,39]. The radioactive decay
curves con¢rmed the in vivo ¢ndings of Rader et al. ApoA-
IIowa was catabolized at a much higher rate than wild type as
shown in Fig. 1A. Serum samples were also analyzed by den-
sity gradient ultracentrifugation and FPLC analysis [24]. The
analysis of serum samples taken after injection of radiola-
belled proteins revealed an altered association of apoA-IIowa
with HDL in contrast to apoA-Iwildÿtype. The density gradient
ultracentrifugation analysis showed an increased association
of apoA-IIowa with the more dense HDL3 particles, whereas
apoA-Iwildÿtype was primarily associated with the HDL2 frac-
tion (Fig. 1B). The FPLC analysis showed two apoA-I con-
taining peaks. The ¢rst one contained the larger HDL par-
ticles, which were composed of apoA-Iwildÿtype and trace
amounts of apoA-IIowa whereas the second peak contained
the majority of apoA-IIowa (Fig. 1C).
5. Discussion
The mechanisms how speci¢c mutations of apoA-I lead to
amyloid deposition have not been revealed yet. Interestingly,
there are some similar features of all four known amyloido-
genic apoA-I variants. The genetic trait is autosomal domi-
nant. All three point mutations are based on a substitution of
a neutral amino acid by the cationic amino acid arginine. This
change in the net charge of the protein results in a character-
istic shift in its isoelectric point [30,34^36]. The deletion/inser-
tion mutation also resulted in an additional positive charge of
the protein with the corresponding shift in isoelectric focus-
sing. All four amyloidogenic mutations are located in the N-
terminal end of apoA-I (Fig. 2). All four mutations resulted in
amyloid deposits containing N-terminal fragments of the var-
iant protein. The identi¢ed N-terminal fragments are of sim-
ilar length (residues 1^83 to 1^94) (Fig. 2). Since the HDL
levels were not reported for all a¡ected subjects, it is not
known whether decreased HDL is a characteristic ¢nding in
all patients.
There are also reports about other mutants of the apoA-I
gene resulting into an additional positive charge, which in
contrast do not cause amyloidosis. The variants apoA-
IGiessen (Pro143-Arg), apoA-IFin (Leu159-Arg), and apoA-IOslo
(Leu160-Arg) have also a substitution of a neutral amino
acid with the positive charged arginine. The a¡ected members
have a decreased HDL concentration presumably due to rapid
catabolism. However, they do not have any signs of amyloid-
osis [40^42]. This observation clearly shows that the location
of the mutation determines whether the apoA-I is amyloido-
genic. The arginine substitution within the N-terminal end of
apoA-I, but not within the middle or carboxy-terminal end,
results in amyloid deposits.
In this respect the observation of Matsunaga et al. is very
interesting. They reported about a mutation of apoA-I which
is de¢ned by a nonsense mutation in codon 84 of the apoA-I
gene, predicting the synthesis of a truncated 1^83 N-terminal
apoA-I. The clinical picture of the patient includes apoA-I
and HDL de¢ciency, atherosclerosis, but no amyloidosis so
far. Since the apoA-I of the patient is not detectable in plasma
or in the HDL fraction by electrophoretic methods or radial
immunodi¡usion techniques, this truncated apoA-I may not
be secreted at all. This may explain why the patient is not
a¡ected by amyloidosis [43]. The crucial question if this mu-
tant of apoA-I is secreted has to be addressed in the future.
The detection of secreted apoA-I1ÿ83 within the serum, but
not within the tissue as amyloid, would underline the impor-
tance of the additional positive charge of the reported amy-
loidogenic mutations. In this respect there is some evidence
that even a secreted apoA-I1ÿ83 may not cause amyloidosis.
Kunitake et al. detected fragments of apoA-I in vivo, includ-
ing one N-terminal fragment of a length of about 10 kDa,
which is very similar to the fragments seen in apoA-I induced
amyloidosis. However, this fragment was detected in healthy
subjects with no clinical signs of amyloidosis. In addition, we
also observed the generation of an apoA-I fragment of the
exact size in vitro. We expressed apoA-I in E. coli, CHO cells,
and in Sf9 cells [15,24,44]. ApoA-I was puri¢ed either from
cell lysates (E. coli and Sf9 cells) or from cell medium. The
isolation of apoA-I revealed in all applied techniques the pres-
ence of an N-terminal 10-kDa fragment, although tissue dep-
osition in radiolabeled in vivo studies was not detectable [24].
Thus the appearance of the 10-kDa apoA-I fragment may
re£ect the physiologic pathway of catabolized apoA-I.
There is some evidence that the reported amyloidogenic
mutations of apoA-I alter its structural conformation. The
residue methionine within polypeptides is in general sensitive
to oxidation during puri¢cation procedures. The amino acid
sequence of apoA-I contains three methionine residues at po-
sition 86, 112, and 148 (Fig. 2). Von Eckardstein et al. showed
that the methionine residues at position 112 and 148 are usu-
ally modi¢ed to methionine sulfoxide during puri¢cation pro-
cedures using chromatographic methods, but not methionine
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Fig. 2. The predicted secondary structure of apoA-I is presented.
The location of the amyloidogenic mutations of apoA-I are indi-
cated by arrows. The domain which is susceptible for cleavage is
marked with a dark rectangle. The three methionine residues of
apoA-I are also indicated. The domain containing one of the class
Y amphipathic helices and the postulated hinged domain is marked
with light grey.
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at position 86. This methionine residue seems to be highly
protected against oxidation, presumably as a result of the
conformational structure of the protein [45]. In contrast,
mass spectroscopic analysis of apoA-I fragments isolated
from amyloid ¢brils showed an oxidized methionine residue
at amino acid position 86. These data con¢rm the hypothe-
sized alteration in the conformational structure of the amy-
loidogenic apoA-I.
We revealed an increased catabolism of apoA-IIowa and al-
tered association of apoA-IIowa with the HDL fraction com-
pared to apoA-Iwildÿtype con¢rming the data of Rader et al..
The apoA-IIowa seems to be associated with smaller and more
dense HDL particles than apoA-Iwildÿtype as could be shown
in the density gradient ultracentrifugation and FPLC analysis.
The phenomenon of decreased association of apoA-I with
HDL and increased metabolism of apoA-I has been shown
before [15,24]. There is accumulating evidence that once
apoA-I dissociates from HDL it is rapidly catabolized [46].
We therefore believe that the amyloidogenic apoA-I variants
with the additional positive charge in their N-terminal end
result into a change of their secondary and/or tertiary struc-
ture. This altered conformation decreases the ability of apoA-
IIowa to associate with the HDL particle, which in turn causes
rapid catabolism. Since apoA-I is very sensitive to proteolysis
it may be cleaved intra- and/or extravascularly. The amyloid
deposits caused by human apoA-I were all composed of var-
iant apoA-I, but not of apoA-Iwildÿtype. Thus, the additional
positive charge within the L-pleated domain of apoA-I deter-
mines the fate of amyloid deposits. There is one report in
which in trace amounts the intact mutant apoA-I (Leu60-
Arg) was found besides the mentioned fragments in the ¢brils.
Therefore, the location of the cleavage (blood vs. tissue) of
amyloidogenic apoA-I remains to be elucidated.
Interestingly, the amyloidogenic mutations of apoA-I occur
distantly from the site of proteolysis. The mutations occur
between residue 26 and 60 (71) resulting all in fragments of
almost identical size (apoA-I1ÿ83 to apoA-I1ÿ94). Remarkably,
apoA-I is not predicted to be an amyloidogenic protein by its
secondary structure. The majority of amyloid proteins have
extensive L-sheet con¢guration, whereas in apoA-I the K-helix
is the dominating structural component. The content of K-
helix in the lipid free apoA-I was about 40^50%, which in-
creases up to 70^80% once it associates with phospholipids
[47]. Only the very N-terminal end of apoA-I is composed
of L-sheet con¢guration. The predicted structural features of
apoA-I are greatly reviewed in [47]. The recently published
crystal structure of a truncated apoA-I (v(1^43)A-I) con-
¢rmed the predicted structural data [48].
The domain of apoA-I which seems to be sensitive for
cleavage contains some interesting structural features. One
of the general characteristic features of apoA-I are repeats
of 11 amino acids forming amphipathic helices. Segrest et
al. ¢rst described the amphipathic helix as a structure/function
motif involved in lipid interaction [49]. An amphipathic helix
is de¢ned as an K-helix with polar amino acids on one site and
non-polar amino acids on the opposite site orientated along
the axis of the helix. Anatharamahiah et al. grouped the am-
phipathic helices upon their physico-chemical and structural
properties into several classes. The most prevalent and char-
acteristic amphipathic helix for apoA-I is the class A amphi-
pathic helix [50]. Class Y amphipathic helices were proposed
at amino acid positions 88^121 and 209^241. A modi¢ed
Class G amphipathic helix is only present in the very N-ter-
minal end of apoA-I [47]. Interestingly, a change from class
A-helix to class Y-helix occurs exactly in the domain where
proteolysis was observed (residue 88, Fig. 2). A change in the
class of amphipathic helices is correlated with a change in the
hydrophobic moment. The distribution of positively, nega-
tively or neutral amino acids on the helix alters the helix class
from A to Y. This modi¢ed distribution of amino acids on the
helix is known to change the ability to associate with lipopro-
tein surfaces [51]. Another aspect is interesting for this do-
main. ApoA-I has a postulated hinged domain, that describes
a mobile region of one or two amphipathic helices which can
either be associated with the lipoprotein surface or can be
released from the lipoprotein surface [52,53]. The hinged do-
main is a proposed LCAT-activating domain, and a domain
probably involved in the cholesterol e¥ux [47]. The hinged
domain has been hypothesized to play an important role in
both the conversion from nascent HDL particles to spheric
HDL particles and the regulation of size and composition of
the HDL particle [50,53]. It is of interest that the hinged
domain is discussed to be a part of the class Y amphipathic
helix region of the apoA-I structure (amino acids 88^121)
(Fig. 2) [50,53,54]. One can speculate that the altered struc-
tural conformation of amyloidogenic apoA-I may result in a
¢xed position which makes the protein susceptible for cleav-
age and may be even susceptible for tissue deposition.
6. Conclusions
The similar features of the four so far known amyloidogen-
ic apoA-I variants suggest a similar mechanism for cleavage
and deposition of the observed apoA-I fragments. The addi-
tional positive charge within the N-terminal domain of apoA-
I leads presumably to an alteration in the conformation of the
variant proteins. This conformational change may cause an
altered association with the HDL particle, which in turn re-
sults in increased catabolism, as shown in our experiments. It
has been reported that the methionine residue at position 86
of apoA-I is usually protected against oxidation with the ex-
ception of the studied amyloidogenic apoA-I variant con¢rm-
ing the altered conformation. This new conformation may
explain an increased susceptibility for apoA-I proteolysis,
which is known for non-lipid bound apoA-I. The postulated
hinged domain may be positioned at an open angle as a target
for proteases. However, the proteolysis may also occur once
the amyloidogenic apoA-I is extravascular. Finally, whether
apoA-I is regularly catabolized or deposited within the tissue
forming amyloid is determined within its N-terminal domain.
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